ArticleXenobiotica; the fate of foreign compounds in biological systems2026
Mass balance and metabolite profiling of
Robert B MacArthur, Sem A O F Rikken, Spandana R Vootukuri, Barry S Coller, C Michael Gibson, Christopher B Granger, G Montalescot, Jurriën M Ten Berg, Murray P Ducharme, Arnoud W J van 't Hof
Abstract readClinical Trial, Phase I
In one paragraphArticle in Xenobiotica; the fate of foreign compounds in biological systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Robert B MacArthurDepartment of Pharmacy Services, Rockefeller University Hospital, New York, NY, USA.ORCID 0000-0002-3264-4666 Spandana R VootukuriLaboratory of Blood and Vascular Biology, Rockefeller University, New York City, NY, USA.ORCID 0000-0002-4478-712X Barry S CollerLaboratory of Blood and Vascular Biology, Rockefeller University, New York City, NY, USA.ORCID 0000-0002-9078-7155 G MontalescotSorbonne Université, ACTION Study Group, ICAN-Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.ORCID 0000-0003-0824-6809 Jurriën M Ten BergDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Murray P DucharmeLearn and Confirm Inc, Montréal, Canada.
Arnoud W J van 't HofCardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.ORCID 0000-0002-2344-7564 Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MPlatelet Integrin AlphaIIbBeta3 Structure, Activation, and Ligand Binding: Fibrinogen, Fibrin, D-dimer, and von Willebrand FactorR01HL019278 · NHLBI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Claudia Lorena Buitrago, Barry Coller · 1985 to 2026
$17.6MNCATS NIH HHS UL1 TR001866NHLBI NIH HHS R01 HL019278
6 · The paper itselfAbstract
The human metabolic and excretion profile of zalunfiban, a novel glycoprotein IIb/IIIa inhibitor, was studied in a phase 1 clinical trial.
Indexed as
AdultCarbon RadioisotopesFemaleHumansInjections, SubcutaneousMaleMiddle AgedCarbon Radioisotopes14C-radiolabeledDrug absorptiondrug excretiondrug metabolismGPIIb/IIIa inhibitormass balancepharmacokineticSTEMIzalunfiban
Identifiers
PMID41328732
PMCPMC13108699
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390